Category: Cardium Therapeutics
Cardium hands federal regulators all necessary paperwork for a new 510(k) submission of its Excellagen wound care product.
Cardium Therapeutics (NYSE:CXM) appealed to U.S. federal regulators for 510(k) clearance of its Excellagen wound care product after making several modifications and including more specific labeling.
Cardium Therapeutics says the European Patent Office hands it a win in a patent war with Boston Scientific over cardiovascular gene therapy technology.
Bankers' confidence in U.S. initial public offering growth for 2012 takes a heavy hit, as China tops the international list for largest IPO market in 2011.
Bankers aren't expecting much excitement in the U.S. market for initial public offerings this year, as China spends another year at the top.
About half of the 100 capital markets execs surveyed predict growth in IPOs this year, compared to 72% of those surveyed in advance of 2011, according to BDO USA, an accounting and consulting firm.
Only 16% of those surveyed expected any growth to be "significant," while 35% expect flat growth and 15% predicted that the market will continue to slide.
Zoll's stock jumped by nearly a quarter overnight after the release of its 2011 earnings report revealing record sales and profits for 2011; plus, Bovie Medical's Q3 profits soar despite sales slide; Cardium Therapeutics pares Q3 losses; Daxor Corp. swings to Q3 loss; Derma Sciences grows Q3 sales, losses; Edap swings to Q3 profits; Fonar Corp.'s Q1 sales, earnings rise; sales plunge as Imris swings to Q3 red; InspireMD's Q3 sales, losses increase; Oridion's Q3 sales, earnings rise; sales down as Patient Safety Technologies swings to Q3 loss; PLC Systems boosts Q3 sales, losses soar; Sanuwave cuts Q3 losses despite lower sales; and Tengion's Q3 losses mount.
Zoll reported record numbers in its top and bottom line for fiscal year 2011, sending its stock up 23 percent overnight.
Zoll shares were trading at $44.35 in the early afternoon today, up from last night's $35.98 close.
The company's 2011 sales hit a record high of $523.7 million, 18 percent higher than the $444 million posted last year.